Peter K. Miller - Jan 11, 2022 Form 4 Insider Report for OptiNose, Inc. (OPTN)

Role
Chief Executive Officer, Director
Signature
/s/ Anthony Krick, Attorney-in-Fact
Stock symbol
OPTN
Transactions as of
Jan 11, 2022
Transactions value $
$0
Form type
4
Date filed
1/12/2022, 02:57 PM
Previous filing
Dec 17, 2021
Next filing
Mar 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OPTN Common Stock Award $0 +216K +31.17% $0.00 907K Jan 11, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OPTN Stock Option (Right to Buy) Award $0 +222K $0.00 222K Jan 11, 2022 Common Stock 222K $1.85 Direct F2
transaction OPTN Stock Option (Right to Buy) Award $0 +250K $0.00 250K Jan 11, 2022 Common Stock 250K $1.85 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the grant of restricted stock units (RSUs). Twenty-five percent (25%) of the RSUs vest on January 11, 2023, and the balance vests in equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer. Each RSU represents the right to receive one share of common stock of OptiNose, Inc.
F2 The option vests and becomes exercisable over a four-year period commencing on January 11, 2022. Twenty-five percent (25%) of the option vests and becomes exercisable on January 11, 2023, and the balance vests in equal monthly installments (rounded down to the nearest whole share) over the remaining three years of the four-year period, subject to continued service with the Issuer.
F3 Represents the maximum number of options eligible to vest during the 4-year vesting period subject to the achievement of certain performance-based objectives relating to the trading price of OptiNose, Inc. common stock. If the minimum performance criteria relating to the trading price of OptiNose, Inc. common stock is not achieved, then none of the options will be eligible to vest.
F4 The option vests and becomes exercisable over a four-year period, commencing on January 11, 2022, subject to the achievement of certain performance-based objectives relating to the trading price of OptiNose, Inc. common stock and continued service with the Issuer.